Show Me the Money: Why Companies Overpay MCOs--and How They Can Stop
To get on formularies, drug companies pay MCOs too much in rebates and get too little market share in return. But "fair share" analysis can help yield big revenue gains as well as giving drug companies the tools to make business-improving tradeoffs within their product portfolios. Key analyses and related interventions can help return to manufacturers some of the market power and negotiating leverage that is shifting from pharma companies to MCOs.
You may also be interested in...
The European Medicines Agency’s clinical data publication policy is on hold, but calls are growing for the regulator to start publishing trial data for COVID-19 treatments and vaccines as soon as they are authorized in the EU.
Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.